2026-10-18T23:47:45Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/123372026-10-18T21:13:21Zopenairedrivercom_ebyu_10000col_ebyu_10001

Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study; [Atriyal Fibrilasyon Hastalarında Gerçek Yaşam Antikoagülan Tedavi Tercihlerinin Değerlendirilmesi: Çok Merkezli ROTA Çalışması Verileri]Kocabaş, UmutErgin, IşılYavuz, VeyselMurat, SeldaÖzdemir, IbrahimGenç, ÖmerAltın, CihanTüner, HaşimMeriç, Bengisu KeskinÇoner, AliYüce, Elif İlkayBoyraz, BedrettinAslan, OnurDal, AhmetŞen, Tanerİbişoğlu, ErsinErdoğan, AslanÖzgeyik, MehmetDemir, MevlütBilgel, Ziya GökalpŞengör, Büşra GüvendiUrgun, Örsan DenizDoğduş, MustafaTekin, Deniz Dilan NakiÇakal, SinemÇayırlı, SercanGüler, ArdaKarabulut, DilayDalgıç, OnurUzman, OsmanMurat, BektaşŞahin, ŞeydaKarabulut, UmutKıvrak, TarıkCoşgun, Muharrem SaidÖzyurtlu, FerhanKaplan, MehmetÖzçalık, EmreanticoagulationAtrial fibrillationdirect oral anticoagulantsstrokesystemic embolismAdministration, OralAdultAgedAged, 80 and overAnticoagulantsDabigatranEmbolismFemaleHumansMaleMiddle AgedProspective StudiesPyridonesRivaroxabanVitamin KYoung Adultacetylsalicylic acidamiodaroneanticoagulant agentantivitamin Kapixabanbeta adrenergic receptor blocking agentclopidogreldigoxindiltiazemObjective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation. Materials and Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation. © 2023 Turkish Society of Cardiology. All rights reserved.Turkish Society of Cardiology2023Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12337https://doi.org/10.5543/tkda.2022.984551016-5169enTurk Kardiyoloji Dernegi Arsiviinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12337